In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 are going to be provided as "insert-on" therapy. In https://abbv-744-in-the-treatment47891.rimmablog.com/31420111/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml